Trial Profile
Double-Blind Placebo-Controlled Study of Escitalopram in the Treatment of Dysthymic Disorder
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 14 Jan 2020
Price :
$35
*
At a glance
- Drugs Escitalopram (Primary)
- Indications Dysthymic disorder
- Focus Therapeutic Use
- 06 Jun 2012 Additional lead trial investigator (David J. Hellerstein) identified as reported by ClinicalTrials.gov.
- 06 Jun 2012 Actual end date (Jan 2009) added as reported by ClinicalTrials.gov.
- 05 Jun 2007 Status changed from recruiting to completed